Biosimilar User Fees: Industry, FDA Tussle On Ramp-Up Speed For Program

Industry says performance goals should not be phased-in, but FDA says it does not have enough money to be full-strength at launch.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet